Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of front-line TKI (nilotinib, dasatinib and imatinib) in patients with chronic phase chronic myeloid leukemia-A Campus CML Study

Next Previous
Trial Profile

Use of front-line TKI (nilotinib, dasatinib and imatinib) in patients with chronic phase chronic myeloid leukemia-A Campus CML Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms Campus CML Study

Most Recent Events

  • 14 Dec 2021 Results (n=332) the use of frontline TKI therapy in a large and unselected cohort of very elderly CP-CML patients assessing presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results evaluating achievement of early molecular response and incidence of events leading to a TKI change during the 1st year of therapy, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 13 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top